Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use INLYTA safely and effectively. See full prescribing information for INLYTA. INLYTA® (axitinib) tablets, for oral administration Initial U.S. Approval: 2012
Medication labelWhy this: Advisory · dailymed-prescription
INLYTA in combination with avelumab is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC). INLYTA in combination with pembrolizumab is indicated for the first-line treatment of patients with advanced RCC. INLYTA as a single agent is indicated for the treatment of advanced RCC after failure of one prior systemic therapy.
- generic_name
- axitinib
- product_names
- axitinib
- ndc
- 63539-044, 63539-044-01, 63539-044-02, 63539-026, 63539-026-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en